Pharmacogenomic study of lamotrigine

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19785
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Psychiatric science
• Research Institution: Fujita Health University
• Principal Investigator: saito takeo 藤田保健衛生大学, 医学部, 講師 (30767611)
• Research Collaborator: Ikeda Masashi 藤田保健衛生大学, 医学部, 准教授 (60424933)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: ラモトリギン / ファーマコゲノミクス / 薬理遺伝学

Outline of Final Research Achievements

Lamotrigine (LTG) induces severe cutaneous adverse drug reactions (cADRs), which are life-threatening events. Therefore, the use of LTG is significantly restricted and biomarker to predict the onset of this event is optimal. For this purpose, recent pharmacogenetic/pharmacogenomic (PGt/PGx) studies have conducted intensively and suggested that particular Human leukocyte antigen (HLA) alleles were strongly associated with cADRs.
In this study, we aim to detect the responsible HLA alleles for LTG-induced cADRs in the Japanese population through a classical HLA typing (HLA-A, HLA-C, HLA-B, and HLA-DRB1). In this association analysis (cADRs case102 vs tolerant controls 198), a specific allele of HLA-DRB1 showed trend for association with LTG-induced cADRs. However, due to limited sample size, more statistical power is warranted to detect significant association. Therefore, further investigation with the larger sample size is essential to validate this association.

Free Research Field

精神科遺伝学